Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced members of its management team will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, Jan. 15, at 3:45pm PT (6:45pm ET).
鹽湖城，2025年1月8日（全球Newswire）-- 萬基遺傳公司（納斯達克：MYGN），基因測試和精準醫療的領導者，今天宣佈其管理團隊成員將在1月15日（星期三）下午3:45（太平洋時間）在舊金山舉行的第43屆摩根大通醫療保健會議上進行演講。
The presentation will be available through a live webcast in the investor relations section of Myriad's website at investor.myriad.com. An archived edition of the presentation will be available later that day.
此次演講將在萬基遺傳公司網站的投資者關係部分通過直播網絡廣播，演講的錄像將於當天稍晚可用。
About Myriad Genetics
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit .
關於Myriad Genetics
萬基遺傳是一家領先的基因檢測和精準醫療公司，致力於提升所有人的健康和幸福。萬基開發並提供基因檢測，幫助評估患病風險或疾病進展，並在醫療專業領域指導治療決策，在這些領域，基因洞察可以顯著改善患者護理並降低醫療成本。欲了解更多信息，訪問。
Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com
投資者聯繫
馬特·斯卡洛
(801) 584-3532
IR@myriad.com
Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com
媒體聯繫
格倫·法雷爾
(385) 318-3718
PR@myriad.com
譯文內容由第三人軟體翻譯。
